Immunotherapy combined with BCG vaccine drastically lowers tuberculosis relapse risk

Immunotherapy combined with BCG vaccine drastically lowers tuberculosis relapse risk

Tuberculosis (TB) remains one of the world's leading causes of death, and preventing post-treatment relapse continues to be a major worldwide health challenge.

Boosted Bacille Calmette-Guérin vaccine strategy significantly reduces tuberculosis relapse, scientists find

Tuberculosis (TB) remains one of the world's leading causes of death, and preventing post-treatment relapse continues to be a major global health challenge. But a new study led by scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI) reveals that combining an immunotherapy with the traditional Bacille Calmette-Guérin (BCG) vaccine drastically lowers the risk of TB relapse in preclinical models.